B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

ABCC1

MOLECULAR TARGET

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

UniProt: P33527NCBI Gene: 436317 compounds

ABCC1 (ATP binding cassette subfamily C member 1 (ABCC1 blood group)) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ABCC1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Daunorubicin1.614
2Apigenin 5,7,4'-trihydroxy-flavone,1.102
3Kaempferols1.102
4Quercetin1.102
5Rimonabant1.102
6myricetin-3-O-galactopyranoside [Supplementary Concept]0.691
7Kaempferols0.691
8Abacavir0.691
9Dehydroepiandrosterone Sulfate0.691
10Delavirdine0.691
11Emtricitabine0.691
12Flurandrenolone0.691
13Indomethacin0.691
14Lamivudine0.691
15tiopronin0.691
16Triamcinolone0.691
17Triamcinolone Acetonide0.691

About ABCC1 as a Drug Target

ABCC1 (ATP binding cassette subfamily C member 1 (ABCC1 blood group)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented ABCC1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ABCC1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.